Antares Pharma, Inc.
ATRS
ATRS was delisted on the 23rd of May, 2022.
101 hedge funds and large institutions have $157M invested in Antares Pharma, Inc. in 2018 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 30 increasing their positions, 24 reducing their positions, and 15 closing their positions.
111% more call options, than puts
Call options by funds: $560K | Put options by funds: $266K
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
25% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 24
23% more capital invested
Capital invested by funds: $128M → $157M (+$29.3M)
1% less funds holding
Funds holding: 102 → 101 (-1)
7% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MWP
MYCIO Wealth Partners
Philadelphia,
Pennsylvania
|
+$6.06M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$2.53M |
| 3 |
BlackRock
New York
|
+$1.65M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$1.22M |
| 5 |
Russell Investments Group
London,
United Kingdom
|
+$610K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$1.27M |
| 2 |
GC
Guggenheim Capital
Chicago,
Illinois
|
-$1.17M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$1.1M |
| 4 |
TF
TIAA FSB
Jacksonville,
Florida
|
-$1.08M |
| 5 |
California Public Employees Retirement System
Sacramento,
California
|
-$800K |
ATRS Hedge Fund Activity: Q2 2018 in Review
101 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Antares Pharma, Inc. (ATRS) for Q2 2018, worth a combined $157M — up 23% from $128M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of ATRS and 14 opened new positions — a net loss of 1 holder — while 24 trimmed existing stakes and 30 added.
The largest buyer was MYCIO Wealth Partners, opening a new position worth an estimated $6.06M. The largest seller was Armistice Capital, cutting an estimated $1.27M.
- 101 institutional investors held Antares Pharma, Inc. (ATRS) as of Q2 2018, down from 102 in Q1 2018.
- Funds reported $157M of Antares Pharma, Inc. stock for Q2 2018, up 23% quarter-over-quarter.
- 14 funds opened new Antares Pharma, Inc. positions in Q2 2018 and 15 closed out, a net change of -1 holder.
- The largest Antares Pharma, Inc. buyer in Q2 2018 was MYCIO Wealth Partners, an estimated $6.06M added.
- The largest Antares Pharma, Inc. seller in Q2 2018 was Armistice Capital, an estimated $1.27M sold.
Based on aggregated 13F filings for Q2 2018.